iVexSol

iVexSol is a viral vector manufacturing company founded on a proprietary, next-generation, stable lentiviral vector production process that transforms the way these essential gene-delivery vehicles are made.

iVexSol has developed a clinically-proven, transformative lentiviral vector (LVV) manufacturing process which addresses the current shortage of LVV, produce.

iVexSol was founded in 2019 and is headquartered in Worcester, Massachusetts.

 

iVexSol’s LVV technology is designed to reliably produce LVV at significantly greater quantities than traditional transient transfection processes, enabling a smaller manufacturing footprint, and facilitating the rapid scale-out needed for global demand.

 

iVexSol's Intelligent Vector Solutions(TM) can be used to manufacture ANY LENTI, ANY SCALE(TM) to provide their clients an END TO END solution, speeding their development and securing their supply chain.

 

iVexSol is backed by Casdin Capital, BioLife Solutions, and others. The commpany closed a $13M Series A round on Dec 01, 2020. This brings iVexSol's total funding to $15.2M to date.

 

 

  • Year founded: 2019
  • Funding Info: $15.2M over 3 Rounds (Latest Funding Type: Series A)
  • Yearly Revenue: NA
  • Employee Size: 2-10
  • Business Valuation: NA
  • City/Town: Worcester
  • State: Massachusetts
  • Country: United States
Related businesses